Amgen Obesity Drug Cut Weight In Closely Watched Study Study ... that the company is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned that it is ...

Stocks were higher Tuesday afternoon as investors digested earnings reports from several retailers and awaited results from ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...

Amgen Inc.’s stock was down 7% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed ...

Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even ...

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...

MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being unclear if these are placebo adjusted. MariTide’s weight ...

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

Amgen stock was dropping sharply Tuesday after releasing what looked like positive data from a Phase 2 study for its ...

MarTide, the new weight loss drug from Amgen, works. Not just well enough for Wall Street. Shares of the Thousand Oaks-based biotech giant fell 10% on Nov. 26 after it announced that MarTide's latest ...

Amgen Inc. announced on Tuesday that its experimental weight-loss drug, MariTide, demonstrated an average weight reduction of ...